In Subramani et al. (2013), the authors describe the autologous immune enhancement therapy (AIET) for a stage IV colonic cancer patient who had already received first-line chemotherapeutic drugs. The procedure includes

1. Aspiration of peripheral blood from the patient
2. Isolation of natural killer (NK) cells and T-lymphocytes from the peripheral blood mononuclear cells (PBMCs (monocytes, lymphocytes, dendritic cells))
3. Activation and 14-day ex vivo expansion with IL-2 of these cells (Method described in Takada, Terunuma, Deng et al. – Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer 18: 64-67, 2011)
4. Intravenous transfusion to the patient.

In this case, Subramani et al. (2013) report a decrease of the carcinoembryonic antigen (CEA) from 901 to 437 U/ml after six infusions of AIET. Furthermore, they observed a regression of lesions and no adverse reactions during the course of the therapy.

Concluding, the authors suggest the described AIET as a promising anticancer approach to eradicate tumor cells, in combination with other conventional therapies (Subramani, et al., 2013).